An evaluation of Debrisan in chronic leg ulcers and pressure sores.
Debrisan (Dextranomer) was subjected to a simple open assessment in the treatment of fifty-three chronic leg ulcers and thirty pressure sores in eight hospitals. It was found that 70% of leg ulcers and 76% of pressure sores improved, with a noticeable cleansing effect being evident in 79% and 83% respectively. No side-effects were recorded.
D000328:Adult; D000368:Aged; D002908:Chronic Disease; D003911:Dextrans / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007871:Leg Ulcer / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D003668:Pressure Ulcer / Q000628:therapy*
D003911:Dextrans